Decreased expression of T lymphocyte co-stimulatory molecule cd26 on invariant natural killer t cells in systemic lupus erythematosus

Immunological Investigations

Volumn 38, Issue 5, 2009, Pages 350-364

  Wong, P T Y ^a   Wong, C K ^a   Tam, L S ^a   Li, E K ^a   Chen, D P ^a   Lam, C W K ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

CD26; Invariant natural killer T cells; Systemic lupus erythematosus

Indexed keywords

CD19 ANTIGEN; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MONOCYTE; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD26; CHEMOKINE CCL2; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NATURAL KILLER T-CELLS; TH1 CELLS;

EID: 70350608299     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130902770003     Document Type: Article

References (40)

1. Ajami, K., Pitman, M. R., Wilson, C. H., Park, J., Menz, R. I., Starr, A. E., Cox, J. H., Abbott, C. A., Overall, C. M., Gorrell, M. D. (2008). Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 582: 819-825.
2. Araki, M., Kondo, T., Gumperz, J. E., Brenner, M. B., Miyake, S., Yamamura, T. (2003). Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15: 279-288.
3. Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X. M., Bollaert, W., Lambeir, A. M., Durinx, C., Goossens, F., Haemers, A. (1999). The unique properties of dipeptidylpeptidase IV (DPPIV/CD26) and the therapeutic potential of DPPIV inhibitors. Curr. Med. Chem. 6: 311-327.
4. Baggiolini, M. (1998). Chemokines and leukocyte traffic. Nature 392: 565-568.
5. Beyan, E., Beyan, C., Turan, M. (2007). Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology 12: 257-2561.
6. Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H. (1992). the Committee on Prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 35: 630-640.
7. Busso, N., Wagtmann, C., Herling, V., Chobaz-Péclat, V., Bischof-Delaloye, A., So, A., Grouzmann, E. (2005). Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 166: 433-442.
8. Cheng, H. C., Abdel-Ghany, M., Elble, R. C., Pauli, B. U. (1998). Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem. 273: 24207-24215. (Pubitemid 28435768)
9. Constantinescu, C. S., Kamoun, M., Dotti, M., Farber, R. E., Galetta, S. L., Rostami, A. (1995). A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. J. Neurol. Sci. 130: 178-182.
10. Green, M. R., Kennell, A. S., Larche, M. J., Seifert, M. H., Isenberg, D. A., Salaman, M. R. (2007). Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IgG production. Arthritis Rheum. 56: 303-310.
11. Gutheil, W. G., Subramanyam, M., Flentke, G. R., Sanford, D. G., Munoz, E., Huber, B. T., Bachovchin, W. W. (1994). Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc. Natl. Acad. Sci. USA 91: 6594-6598.
12. Huang, L., Cheng, H. C., Isom, R., Chen, C. S., Levine, R. A., Pauli, B. U. (2008). Protein kinase Cepsilon mediates polymeric fibronectin assembly on the surface of blood-borne rat breast cancer cells to promote pulmonary metastasis. J. Biol. Chem. 283: 7616-7627.
13. Jensen, J., Langkilde, A. R., Fenst, C. Nicolaisen, M. S., Roed, H. G., Christiansen, M., Sellebjerg, F. (2004). CD4 T cell activation and disease activity at onset of multiple sclerosis. J. Neuroimmunol. 149: 202-209.
14. Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., Kinashi, T., Tanaka, T., Miyasaka, M., Nagai, H., Ushikubi, F., Narumiya, S. (2003). Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat. Immunol. 4: 694-701.
15. Kobayashi, H., Hosono, O., Mimori, T. Kawasaki, H., Dang, N. H., Tanaka, H., Morimoto, C. (2002). Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J. Rheumatol. 29: 1858-1866.
16. Kronenberg, M. (2005). Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900.
17. Lambeir, A., M., Durinx, C., Scharpé, S., De Meester, I. (2003). Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40: 209-294.
18. Lit, L. C., Wong, C. K., Tam, L. S., Li, E. K., Lam, C. W. (2006). Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65: 209-215.
19. Lun, S. W. M., Wong, C. K., Ko, F. W. S., Hui, D. S. C., Lam, C. W. K. (2007). Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J. Clin. Immunol. 27: 430-437.
20. McIntosh, C. H. (2008). Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front. Biosci. 13: 1753-1773.
21. Mercer, J. C., Ragin, M. J., August, A. (2005). Natural killer T cells: Rapid responders controlling immunity and disease. Int. J. Biochem. Cell Biol. 37: 1337-1343.
22. Morimoto, C., Lord, C. I., Zhang, C., Duke-Cohan, J. S., Letvin, N. L., Schlossman, S. F. (1994). Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc. Natl. Acad. Sci. USA 91: 9960-9964.
23. Ohtsuki, T., Hosono, O., Kobayashi, H., Munakata, Y., Souta, A., Shioda, T., Morimoto, C. (1998). Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1a by CD26/dipeptidyl peptidase IV. FEBS Lett. 431: 236-240. (Pubitemid 28334224)
24. Oshikawa, K., Sugiyama, Y. (2001). Elevated soluble CD26 levels in patients with tuberculous pleurisy. Int. J. Tuberc. Lung Dis. 9: 868-872.
25. Porcelli, S., Yockey, C. E., Brenner, M. B., Balk, S. P. (1993). Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-CD8- alpha/beta T cells demonstrates preferential use of several Vbeta genes and an invariant TCR alpha chain. J. Exp. Med. 178: 1-16.
26. Preller, V., Gerber, A., Wrenger, S., Togni, M., Marguet, D., Tadje, J., Lendeckel, U., Röcken, C., Faust, J., Neubert, K., Schraven, B., Martin, R., Ansorge, S., Brocke, S., Reinhold, D. (2007). TGF-1-Mediated Control of Central Nervous System Inflammation and Autoimmunity through the Inhibitory Receptor CD26. J. Immunol. 178: 4632-4640.
27. Proost, P., Schutyser, E., Menten, P., Struyf, S., Wuyts, A., Opdenakker, G., Detheux, M., Parmentier, M., Durinx, C., Lambeir, A. M., Neyts, J., Liekens, S., Maudgal, P. C., Billiau, A., Van Damme, J. (2001). Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98: 3554-3561.
28. Racke, M. K., Dhib-Jalbut, S., Cannella, B., Albert, P. S., Raine, C. S., McFarlin, D. E. (1991). Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146: 3012-3017.
29. Reinhold, D., Kähne, T., Steinbrecher, A., Wrenger, S., Neubert, K., Ansorge, S., Brocke, S. (2002). The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol. Chem. 383: 1133-1138.
30. Sakuishi, K., Oki, S., Araki, M., Porcelli, S. A., Miyake, S., Yamamura, T. (2007). Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J. Immunol. 179: 3452-3462.
31. Sen, Y., Yongyi, B., Yuling, H., Luokun, X., Li, H., Jie, X., Tao, D., Gang, Z., Junyan, L., Chunsong, H., Zhang, X., Youxin, J., Feili, G., Boquan, J., Jinquan, T. (2005). V alpha 24-invariant NKT cells from patients with allergic asthma express CCR9 at high frequency and induce Th2 bias of CD3+ T cells upon CD226 engagement. J. Immunol. 175: 4914-4926.
32. Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., McShane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., Winchester, R. J. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277.
33. Tanaka, T., Duke-Cohan, J. S., Kameoka, J., Yaron, A., Lee, I., Schlossman, S. F., Morimoto, C. (1994) Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc. Natl. Acad. Sci. USA 91: 3082-3086.
34. Thompson, M. A., Ohnuma, K., Abe, M., Morimoto, C., Dang, N. H. (2007) CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini. Rev. Med. Chem. 7: 253-273.
35. Tokano, Y., Morimoto, S., Kaneko, H., Amano, H., Nozawa, K., Takasaki, Y., Hashimoto, H. (1999). Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines. Clin. Exp. Immunol. 116: 169-173.
36. Valencia, X., Yarboro, C., Illei, G., Lipsky, P. E. (2007). Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178: 2579-2588.
37. Viallard, J. F., Pellegrin, J. L., Ranchin, V., Schaeverbeke, T., Dehais, J., Longy-Boursier, M., Ragnaud, J. M., Leng, B., Moreau, J. F. (1999). Th1 (IL-2, interferon-gamma (IFNgamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 115: 189-195.
38. Wong, C. K., Ho, C. Y., Li, E. K., Tam, L. S., Lam, C. W. K. (2002). Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 130: 345-351.
39. Wrenger, S., Faust, J., Mrestani-Klaus, C., Fengler, A., Stockel-Maschek, A., Lorey, S., Kahne, T., Brandt, W., Neubert, K., Ansorge, S., Reinhold, D. (2000). Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J. Biol. Chem. 275: 22180-22186.
40. Wrenger, S., Hoffmann, T., Faust, J. Mrestani-Klaus, C., Brandt, W., Neubert, K., Kraft, M., Olek, S., Frank, R., Ansorge, S., Reinhold, D. (1997). The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J. Biol. Chem. 272: 30283-30288.